Krista A. Frankenberry, Ph.D.

Krista A. Frankenberry, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


Dr. Krista Frankenberry has worked extensively on analyzing drug resistance in HIV patients. She and her colleagues have identified mutations outside of the expected drug target regions of HIV (connection domain in reverse transcriptase) that have led to the discovery of novel mechanisms of NRTI and NNRTI drug resistance. In addition, Dr. Frankenberry and colleagues confirmed that the newly discovered virus, XMRV, was not linked to chronic fatigue syndrome or prostate cancer, but instead was the result of contamination. Her work now focuses on developing novel strategies against HIV-1 using gene therapy.

Areas of Expertise

Real-time PCR
Tissue Culture
Molecular Biology Techniques


Selected Publications

A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors

Nikolenko GN, Delviks-Frankenberry KA, Pathak VK
J. Virol. 84: 5238-49, 2010. [ Journal Article ]

HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision

Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, Pathak VK
Proc. Natl. Acad. Sci. U.S.A. 105: 10943-8, 2008. [ Journal Article ]

Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors

Delviks KA, Hu WS, Pathak VK
J. Virol. 71: 6218-24, 1997. [ Journal Article ]

Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2

Delviks-Frankenberry K, Paprotka T, Cingöz O, Wildt S, Hu WS, Coffin JM, Pathak VK
J. Virol. 87: 11525-11537, 2013. [ Journal Article ]

Recombinant origin of the retrovirus XMRV

Paprotka T, Delviks-Frankenberry KA, Cingöz O, Martinez A, Kung HJ, Tepper CG, Hu WS, Fivash MJ, Coffin JM, Pathak VK
Science. 333: 97-101, 2011. [ Journal Article ]